Page last updated: 2024-11-13
hexa-d-arginine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 57358476 |
SCHEMBL ID | 19267519 |
MeSH ID | M000605672 |
Synonyms (16)
Synonym |
---|
hexa-d-arginine amide |
673202-67-0 |
d-argininamide, d-arginyl-d-arginyl-d-arginyl-d-arginyl-d-arginyl- |
hexa-d-arginine , |
CS-7595 |
AKOS024458307 |
n~5~-(diaminomethylidene)-d-ornithyl-n~5~-(diaminomethylidene)-d-ornithyl-n~5~-(diaminomethylidene)-d-ornithyl-n~5~-(diaminomethylidene)-d-ornithyl-n~5~-(diaminomethylidene)-d-ornithyl-n~5~-(diaminomethylidene)-d-ornithinamide |
DTXSID90724127 |
furin inhibitor ii |
SCHEMBL19267519 |
HY-P1028 |
NCGC00505008-01 |
BS-17319 |
D71119 |
d-argininamide d-arginyl-d-arginyl-d-arginyl-d-arginyl-d-arginyl-d-alanine |
d-argininamided-arginyl-d-arginyl-d-arginyl-d-arginyl-d-arginyl-d-alanine |
Research Excerpts
Compound-Compound Interactions
Excerpt | Reference | Relevance |
---|---|---|
" The influence of furin suppression on HBV replication and the effect of CMK combined with nucleoside analog entecavir (ETV) on HBV replication and HBeAg secretion was investigated in HepG2." | ( Entecavir combined with furin inhibitor simultaneously reduces hepatitis B virus replication and e antigen secretion. Gu, L; Li, DM; Peng, XM; Yang, HY; Zheng, NQ, 2014) | 0.4 |
" Moreover, the viral replication-enhancing effect of CMK was abrogated by ETV and ETV combined with CMK reduced HBV replication and HBeAg secretion simultaneously." | ( Entecavir combined with furin inhibitor simultaneously reduces hepatitis B virus replication and e antigen secretion. Gu, L; Li, DM; Peng, XM; Yang, HY; Zheng, NQ, 2014) | 0.4 |
" Nucleotide/nucleoside analogs combined with furin inhibitors may be a potential easy way to realize the dual goals of the antiviral therapy for chronic hepatitis B in the future." | ( Entecavir combined with furin inhibitor simultaneously reduces hepatitis B virus replication and e antigen secretion. Gu, L; Li, DM; Peng, XM; Yang, HY; Zheng, NQ, 2014) | 0.4 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (1)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1347149 | Furin counterscreen qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 17.90
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.90) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (20.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (80.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |